Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 04/24 06:28:48 pm
65.34 EUR   -0.56%
03:15pSANOFI SA : quaterly earnings release
11:35aSANOFI'S VALPRO : Regulator
DJ
10:32aSANOFI : UK bans Sanofi epilepsy drug without pregnancy prevention p..
RE
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi : Signs Agreement with Principia Biopharma for MS Drug Candidate

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/09/2017 | 01:15pm CEST

By Sonia Amaral Rohter

Sanofi SA (SAN.FR) on Thursday said that it has signed a license agreement with Principia Biopharma Inc. to develop an experimental oral treatment for multiple sclerosis, or MS, as part of its efforts to expand its MS franchise.

Under the terms of the deal, Sanofi will be granted an exclusive, worldwide license to develop and commercialize the drug, which is currently under clinical development. Sanofi will make an upfront payment of $40 million to Principia, and Principia will receive future milestone payments of up to $765 million as well as royalties on product sales.

According to the company, the drug candidate, referred to as PRN2246, shows promise in treating MS, a chronic inflammatory disorder of the central nervous system that affects over 2.5 million people worldwide. Principia has recently initiated a phase 1 trial of PRN2246 in healthy volunteers, according to the release.

Sanofi already has two MS medicines on the market, Aubagio and Lemtrada, as well as an in-house research and development program to address MS and other neurological diseases.

"Our agreement with Principia is an example of Sanofi's strategic commitment to build our drug discovery and development pipeline in MS and neurological diseases," says Rita Balice-Gordon, global head of the company's MS/neuroscience therapeutic research area. "Complementing our own internal R&D expertise, external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases."

The transaction, which is subject to customary regulatory approvals, is expected to close in the fourth quarter.

Write to Sonia Amaral Rohter at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
03:15pSANOFI SA : quaterly earnings release
01:55pBAM : Ex-President Aquino couldn't have foreseen Dengvaxia's unintended effects
AQ
01:30pSANOFI : UK bans Sanofi epilepsy drug without pregnancy prevention plan
AQ
11:35aSANOFI'S VALPROATE RESTRICTED FOR SO : Regulator
DJ
10:32aSANOFI : UK bans Sanofi epilepsy drug without pregnancy prevention plan
RE
09:54aBIOCENTURY - MANAGEMENT TRACKS : Probiodrug, Alder
AQ
07:31aSANOFI : Head of Global R&D Elias Zerhouni to retire; Company names John Reed to..
GL
07:31aSANOFI : Head of Global R&D Elias Zerhouni to retire; Company names John Reed t..
AQ
04/23WiseTech Global acquires three leading logistics solution providers across La..
AQ
04/23WISETECH GLOBAL (ASX : WTC) Acquires Three Leading Logistics Solution Providers ..
AQ
More news
News from SeekingAlpha
07:49aSanofi R&D chief to retire in late June 
04/23MANNKIND : Experts In Pulling Numbers From Orifices 
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
04/20Now See Wall Street's 38 'Safer' International Dividend WallStars For April 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
Financials (€)
Sales 2018 35 112 M
EBIT 2018 8 635 M
Net income 2018 4 940 M
Debt 2018 14 433 M
Yield 2018 4,68%
P/E ratio 2018 16,16
P/E ratio 2019 14,30
EV / Sales 2018 2,75x
EV / Sales 2019 2,58x
Capitalization 81 999 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,1 €
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-9.14%100 185
JOHNSON & JOHNSON-9.23%339 783
PFIZER1.13%217 897
NOVARTIS-7.72%204 972
ROCHE HOLDING LTD.-11.72%192 109
MERCK AND COMPANY7.07%158 571